Sotrovimab use in young pediatric patients at high-risk of progression to severe COVID-19 disease.

This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12 to 16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).